Breaking News

Juniper Pharma Adds VP Role

March 30, 2016

Weiss to head Medical Affairs and Clinical Development

Herman Weiss, MD, MBA, FACOG, has been appointed to the newly-created role of vice president, Medical Affairs and Clinical Development at Juniper Pharmaceuticals, Inc.
Dr. Weiss will work with chief medical officer Dr. Bridget Martell to support the development of Juniper's product portfolio, providing medical, clinical and regulatory expertise for current and future product candidates leveraging its delivery technologies.
"We are thrilled to have recruited such a medical talent to Juniper Pharmaceuticals as we advance our high-value pipeline to address acute and chronic women's health conditions into later stages of clinical development," said Frank Condella, chief executive officer. "Herman brings that right balance of clinical acumen, business sense, regulatory experience, and deep understanding of the continued needs in women's health."
Dr. Weiss joins Juniper from Teva Pharmaceutical Industries, Ltd., where he served as Global Medical Director Women's Health and Bone Health. Dr. Weiss was responsible for the global launch of seven products in the contraception, urology, and infertility space, and designed, implemented and oversaw multiple late-stage clinical trials.  He also provided all medical due diligence for business development projects.
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials